Thrombin Metz: characterization of the dysfunctional thrombin derived from a variant of human prothrombin. 1984

M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso

Thrombin Metz and normal thrombin, resulting from activation of the respective prothrombins by factor Xa in the presence of calcium, phospholipid, and factor Va, were purified by chromatography on sulfopropyl Sephadex. By physicochemical criteria, thrombin Metz is identical to normal thrombin. Its functional properties were investigated in some reactions in which thrombin is classically involved. Thrombin Metz exhibits less than 4% of fibrinogen clotting activity. Both Km and Kcat, determined on S2238, are abnormal. Titration with the high-affinity competitive inhibitor of thrombin, DAPA, shows that fluorescence enhancement of the probe is only 34% in binding to thrombin Metz when compared to that observed in binding to normal thrombin. High-performance liquid chromatography has been used to measure the simultaneous rate of release of fibrinopeptides A and B. A decreased release rate for both fibrinopeptides, more marked for fibrinopeptide B, results in a slow fibrin polymerization, as followed by absorbance at 450 nm. Thrombin Metz is less than 5% as effective as normal thrombin in inducing platelet aggregation. Interaction with antithrombin III is slower than normal when followed by SDS gel electrophoresis and inhibition of the amidolytic activity of thrombin on S2238. This abnormality is not observed in the presence of heparin. However, thrombin Metz binds less tightly to a heparin-Sepharose column, and the direct inhibition of heparin on its activity on S2238 is weaker. From these results, we can predict that the defect in thrombin Metz affects the catalytic site or its vicinity and, jointly or consequently, the region of interaction of thrombin with antithrombin III and heparin.

UI MeSH Term Description Entries
D007020 Hypoprothrombinemias Absence or reduced levels of PROTHROMBIN in the blood. Factor II Deficiency,Prothrombin Deficiency,Deficiency, Factor II,Hypoprothrombinemia,Deficiencies, Factor II,Deficiencies, Prothrombin,Deficiency, Prothrombin,Factor II Deficiencies,Prothrombin Deficiencies
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D003619 Dansyl Compounds Compounds that contain a 1-dimethylaminonaphthalene-5-sulfonyl group. Dimethylaminonaphthalenesulfonyl Compounds,Compounds, Dansyl,Compounds, Dimethylaminonaphthalenesulfonyl
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D005345 Fibrinopeptide B Two small peptide chains removed from the N-terminal segment of the beta chains of fibrinogen by the action of thrombin. Each peptide chain contains 20 amino acid residues. The removal of fibrinopeptides B is not required for coagulation. Fibrinopeptides B
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
February 1987, Blood,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
March 1988, Blood,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
December 1979, FEBS letters,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
July 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
January 1981, Annals of the New York Academy of Sciences,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
March 1997, Thrombosis research,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
October 1974, Biochemical and biophysical research communications,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
June 1987, British journal of haematology,
M J Rabiet, and M Jandrot-Perrus, and J P Boissel, and J Elion, and F Josso
August 1983, British journal of haematology,
Copied contents to your clipboard!